Cubist Pharmaceuticals and Emisphere Technologies Announce Research Collaboration for Oral Delivery of Daptomycin CAMBRIDGE, Mass., Nov. 6 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) and Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced a research and development
DuPont Pharmaceuticals and Emisphere Announce Agreement for Oral Heparins Development and Marketing WILMINGTON, Del., and TARRYTOWN, N.Y., June 30 /PRNewswire/ -- DuPont Pharmaceuticals Company, a wholly-owned independent subsidiary of DuPont (NYSE: DD) and Emisphere Technologies, Inc.
ROSELAND, N.J. , May 30, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies , Inc. (OTCBB:EMIS) today announced that its non-prescription medical food product, Eligen B12, has earned the coveted “Amazon’s Choice” designation for being highly rated, fairly-priced, and available to ship immediately by
Emisphere Achieves Second Milestone in Roche Collaboration TARRYTOWN, N.Y., Feb. 15 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has achieved a second milestone under its November 2004 agreement with Roche to develop new oral formulations of a Roche
Emisphere to Receive $7 Million Payment ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS ) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE: NVO ) for the development and
Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product Hawthorne, NY and Dublin, Ireland, January 11, 1999 --- Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) and Elan Corporation, plc (NYSE: ELN) announced that the preliminary results of the Phase II oral
Emisphere and Elan Contribute $10 Million to Heparin Joint Venture Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral
Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements Hawthorne, NY and Indianapolis IN, March 16, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) and Eli Lilly & Co. (NYSE:LLY) announced today that Lilly has executed two license agreements with